Trial reportGastroenterology2011
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
Trial report in Gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 75 citations in OpenAlex.
- Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.PloS one · 2016Trial
- Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.Trials · 2014Trial
- The Antimicrobial Effects of Coffee and By-Products and Their Potential Applications in Healthcare and Agricultural Sectors: A State-of-Art Review.Microorganisms · 2025Review
- Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease.Foods (Basel, Switzerland) · 2024Review
- Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases.Hepatology forum · 2020Article
- Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH).Nutrients · 2020Article
- Maternal Dietary Intake of Omega-3 Fatty Acids Correlates Positively with Regional Brain Volumes in 1-Month-Old Term Infants.Cerebral cortex (New York, N.Y. : 1991) · 2020Article
- Generic chemoprevention of hepatocellular carcinoma.Annals of the New York Academy of Sciences · 2019Review
- Design and in Vivo Characterization of AJournal of medicinal chemistry · 2019Article
- Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B.Nutrients · 2017Article
- Coffee and Liver Disease.Journal of clinical and experimental hepatology · 2016Review
- The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition.The American journal of clinical nutrition · 2015Article
- Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease.World journal of gastroenterology · 2015Review
- I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis.F1000Research · 2015Review
- Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.World journal of gastroenterology · 2014Review
- Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Molecular diagnosis & therapy · 2014Review
- Metabolic factors and chronic hepatitis C: a complex interplay.BioMed research international · 2013Review
- Coffee and liver - long way to go.Journal of clinical and experimental hepatology · 2012Article
- Insulin resistance and chronic liver disease.World journal of hepatology · 2011Article
- Coffee intake linked to improved SVR in patients undergoing treatment for hepatitis C.Annals of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsHigh-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated.
methodsPatients (n=885) from the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with peginterferon α-2a (180 μg/wk) and ribavirin (1000-1200 mg/day). We assessed patients for early virologic response (2 log10 reduction in level of hepatitis C virus RNA at week 12; n=466), and undetectable hepatitis C virus RNA at weeks 20 (n=320), 48 (end of treatment, n=284), and 72 (sustained virologic response; n=157).
resultsMedian log10 drop from baseline to week 20 was 2.0 (interquartile range [IQR], 0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or more cups/day of coffee (P trend<.0001). After adjustment for age, race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend=.004) for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend=.005) for week 20 virologic response, 2.4 (95% CI: 1.3-4.6; P trend=.001) for end of treatment, and 1.8 (95% CI: 0.8-3.9; P trend=.034) for sustained virologic response.
conclusionsHigh-level consumption of coffee (more than 3 cups per day) is an independent predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.